AI Biotech Startup ChemT Raises $5M for Biomanufacturing Platform
Source: Tech in Asia
Singapore-based AI biotech startup ChemT Biotechnology has raised US$4 million in seed funding to bring artificial intelligence to biomanufacturing, bringing total funding to US$5 million within 18 months.
Singapore-based AI biotech startup ChemT Biotechnology has raised US$4 million in seed funding to bring artificial intelligence to biomanufacturing, bringing total funding to US$5 million within 18 months. The round was led by Wavemaker Ventures with participation from Seeds Capital, Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator.
ChemT builds AI platforms targeting Chemistry, Manufacturing, and Controls — the notoriously complex and manual processes behind biologics production. Its CelMo platform simulates how cells behave under different manufacturing conditions, delivering a 50 per cent increase in antibody output and a 40 per cent reduction in production timelines. A second platform, Chemplify, targets cell therapy manufacturing with claims of 50 per cent faster T-cell development and 60 per cent lower costs. Both products have been tested on Chinese Hamster Ovary cells, the industry-standard workhorse for biologics.
The funding will go toward expanding ChemT's AI and experimental infrastructure as the company scales from research validation toward commercial deployment. The investor mix — crossing traditional VC with life-science and Temasek-linked capital — suggests confidence that the platform can address a genuine bottleneck in biopharma: the gap between lab discoveries and scalable manufacturing. For a small island with a growing biotech cluster, ChemT represents a bet on AI as a manufacturing lever, not just a discovery tool.
Why it matters for Singapore: Biomanufacturing is capital-intensive and highly regulated, two areas where AI can deliver outsized returns. Singapore has invested heavily in building a biomedical sciences cluster, and ChemT shows that homegrown startups are targeting the manufacturing layer rather than just drug discovery. If CelMo and Chemplify deliver on their benchmarks, they could give Singapore a differentiated position in AI-driven biologics production at a time when the global cell therapy market is projected to grow rapidly.